Know Cancer

or
forgot password

Usage of Vinorelbin ORAL (Navelbine® ORAL) in the Treatment of Advanced Non-small Cell Lung Cancer(NSCLC)and Advanced Breast Cancer


N/A
18 Years
N/A
Not Enrolling
Both
Non Small Cell Lung Carcinoma, Metastatic Breast Cancer

Thank you

Trial Information

Usage of Vinorelbin ORAL (Navelbine® ORAL) in the Treatment of Advanced Non-small Cell Lung Cancer(NSCLC)and Advanced Breast Cancer


Inclusion Criteria:



- At least 18 years old

- Male and female patients

- Advanced NSCLC (Stage III or IV) or Antracycline-resistant MBC

- Therapy with Navelbine capsules in any palliative treatment line

- Signed patient informed consent

Exclusion Criteria:

- Pregnancy and nursing

- All other exclusion criteria listed in SPC (summary of product characteristics)

- lack of signed Patient informed consent

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

Progression-free-survival

Outcome Time Frame:

1 year after LPI

Safety Issue:

No

Authority:

Germany: Federal Institute for Drugs and Medical Devices

Study ID:

IOM-155

NCT ID:

NCT00890903

Start Date:

March 2009

Completion Date:

April 2012

Related Keywords:

  • Non Small Cell Lung Carcinoma
  • Metastatic Breast Cancer
  • NSCLC
  • non small cell lung carcinoma
  • metastatic breast cancer
  • MBC
  • advanced breast cancer
  • Navelbine
  • Navelbine-ORAL
  • Vinorelbine
  • Vinorelbine-ORAL
  • daily routine
  • concomitant antiemetic therapy
  • patient compliance
  • germany
  • non-interventional study
  • oral anti cancer therapy
  • quality of life
  • Breast Neoplasms
  • Carcinoma
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms

Name

Location